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Background
No data are available about the efficacy of the new oral
one daily chelator deferasirox on cardiac iron and func-
tion versus deferiprone and desferrioxamine. Magnetic
Resonance (MR) is the unique non invasive suitable
technique to quantitatively evaluate this issue.
Aims
Our aim was to prospectively assess the efficacy of the
deferasirox versus deferiprone and desferrioxamine in
monotherapy in a large cohort of thlassemia major
(TM) patients by quantitative MR.
Methods
Among the first 1135 TM patients enrolled in the
MIOT (Myocardial Iron Overload in Thalassemia) net-
work, 392 patients performed a MR follow up study at
18 ± 3 months according to the protocol. We evaluated
prospectively the 193 TM patients who had been
received one chelator alone between the 2 MR scans.
We identified 3 groups of patients: 80 treated with
DFX, 39 treated with DFP and 74 treated with DFO.
Myocardial iron concentrations were measured by T2*
multislice multiecho technique. Biventricular function
parameters were quantitatively evaluated by cine
images.
Results
Excellent/good levels of compliance were similar in the
3 groups (DFX 99%, DFP 95%; DFO 96%, P =0 . 6 ) .
There were no significant differences in all 3 groups to
maintain the patients without significant myocardial
iron overload (global heart T2*≥20 ms) (DFX 98%; DFP
100%; DFO 98%; P=1.0). The percentage of patients that
maintained a normal LVEF (>57%) was significantly
lower in DFX (77%) versus DFP (100%) (P=0.018), it
was no significantly different in DFX and DFO group
(82%) (P=0.59).
Among the patients with myocardial iron overload at
baseline in all 3 groups, there was a significant improve-
ment in the global heart T2* value and in the number
of segment with a normal T2* value; only in the DFP
group there was a significant improvement in the right
global systolic function (+ 6.8% P =0.016). The improve-
ment in the global heart T2* was significantly lower in
the DFX versus the DFP group (P=0.0026), but it was
not significantly different in the DFX versus the DFO
group (mean difference global heart T2* 3.5±4.7 ms ver-
sus 8.8±8.6 ms and versus 3.7±5.5 ms, respectively;
P=0.90) (Figure 1). The changes in the global systolic bi-
ventricular function were not significantly different
among groups.
Conclusions
Prospectively over 15 months in a large clinical setting
of TM patients DFP monotherapy was significantly
more effective than DFX in improving myocardial side-
rosis and in maintaining a normal LVEF, no significant
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